Results

1–7 of 7 results for photobiomodulation

LIGHTSITE IIIB: A Prospective, Multi-Center Extension Study to Assess the Long-Term Safety and Efficacy ofPhotobiomodulation in Dry Age-Related Macular Degeneration
David S. Boyer, MD
Annual Meeting Talks
2025
Multiwavelength Photobiomodulation Significantly Reduces Risk for Vision Loss and Onset of Geographic Atrophy in Dry Age-Related Macular Degeneration
Eleonora Lad, MD, PhD
Annual Meeting Talks
2024
LIGHTSITE IIIB: A Prospective, Multi-Center Extension Study to Assess the Long-Term Safety and Efficacy of Photobiomodulation in Dry Age-Related Macular Degeneration
David S. Boyer, MD
Updates from the Field
2025
Multiwavelength Photobiomodulation Significantly Reduces Risk for Vision Loss and Onset of Geographic Atrophy in Dry Age-Related Macular Degeneration
Eleonora Lad, MD, PhD
Updates from the Field
2024
LIGHTSITE III Analysis: 24-Month Evaluation of Multiwavelength Photobiomodulation
Nathan C. Steinle, MD
Updates from the Field
2024
Efficacy and Safety of Multiwavelength Photobiomodulation in Dry Age-Related Macular Degeneration Using the LumiThera Valeda System (LIGHTSITE III Interim Analysis)
Richard B. Rosen, MD, DSc(Hon), FACS, FASRS, FARVO
Updates from the Field
2022
Photobiomodulation for DME With Good VA: DRCRnet Protocol AE
Judy E. Kim, MD, FASRS
Updates from the Field
2021